No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MDXG MiMedx
- 7.865
- -0.085-1.07%
Trading May 22 14:22 ET
1.16BMarket Cap16.05P/E (TTM)
7.975High7.865Low174.64KVolume7.910Open7.950Pre Close1.38MTurnover0.15%Turnover Ratio21.26P/E (Static)147.60MShares9.27052wk High7.45P/B925.35MFloat Cap5.47052wk Low--Dividend TTM117.65MShs Float18.250Historical High--Div YieldTTM1.38%Amplitude0.309Historical Low7.925Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following
We Believe MiMedx Group's (NASDAQ:MDXG) Earnings Are A Poor Guide For Its Profitability
MiMedx Group, Inc.'s (NASDAQ:MDXG) stock rose after it released a robust earnings report. While the headline numbers were strong, we found some underlying problems once we started looking at what dro
The 20% Return This Week Takes MiMedx Group's (NASDAQ:MDXG) Shareholders Five-year Gains to 148%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more tha
Buy Rating Affirmed for MiMedx on Strong Performance and Favorable Market Outlook
MiMedx Group Up Over 18%, On Track for Largest Percent Increase Since May 2023 -- Data Talk
MiMedx Group, Inc. (MDXG) is currently at $7.28, up $1.12 or 18.18% --Would be highest close since April 1, 2024, when it closed at $7.45 --On pace for largest percent increase since May 3, 2023, wh
Express News | MiMedx Group Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Comments
Mizuho Boosts MiMedx Group's Price Target to $14, Continues Bullish Outlook.
In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx(MDXG.US$
...
In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx(MDXG.US$
...
MIMEDX's Chair and CEO have expressed optimism about the new appointments, stating that Olson and Puhy will contribute to the company's strategic vision and provide valuable insights. Their skills and leadership records will elevate the Board.
CFO Doug Rice asserts the new debt facility offers more flexibility for long-term strategic goals. The terms mirror the company's progress in enhancing its financial profile and reducing interest expense.
Analysts say that MiMedx's low projected revenue growth may contribute to its weak P/S ratio. Significant performance improvements would be needed for a potential P/S ratio rise. The low P/S ratio casts doubt on the company's potential despite its share price increase.
1
Carlson's experience could potentially elevate Spectral AI's position in the market. The potential impact of its breakthrough technology could present substantial opportunities for growth and value in the healthcare industry.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg